Drug intelligence / Profile preview

RNA-100-AR02

Development stage: Approved
Lead developer: Moderna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

RNA-100-AR02 is the active mRNA substance in **MRESVIA**, Moderna's approved respiratory syncytial virus vaccine. It is a **nucleoside-modified mRNA vaccine** formulated as an injectable suspension for **intramuscular** administration; each 0.5 mL dose contains 50 mcg of mRNA. The sequence encodes a **stabilized prefusion RSV F glycoprotein**, leading host cells to transiently express the antigen and induce protective immune responses against RSV lower respiratory tract disease. The product received initial U.S. approval in 2024 and is used for prevention of RSV-associated lower respiratory tract disease in adults, with approved labeling now covering older adults and at-risk adults 18 through 59 years of age.

Brand names: MRESVIA
Other names: respiratory syncytial virus vaccine

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on RNA-100-AR02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA-100-AR02.

Explore the full profile